NexMed, Inc. (NASDAQ: NEXM), a developer of innovative treatments based on the NexACT® technology, today announced that it received a letter from Nasdaq yesterday stating that the market capitalization deficiency of NexMed has been cured. Accordingly, NexMed’s oral hearing scheduled for Thursday, August 17, 2006 is considered moot.
